Kerri Fitzgerald

Articles by Kerri Fitzgerald

Kerri FitzgeraldMantle Cell Lymphoma | January 27, 2023
The FDA approved the first and only noncovalent BTK inhibitor for MCL.
Read More
Kerri FitzgeraldMeeting News | December 21, 2022
Race/ethnicity, income, and access to chemotherapy and radiation therapy improved outcomes in patients with Burkitt lymphoma.
Kerri FitzgeraldMeeting News | December 21, 2022
The cell of origin in patients with diffuse large B-cell lymphoma may impact their response to CAR-T therapy and survival.
Kerri FitzgeraldMeeting News | December 19, 2022
Mutation of CALR in patients with myelofibrosis may be associated with a more anemic phenotype at diagnosis.
Kerri FitzgeraldMeeting News | December 19, 2022
Simultaneous treatment with ponatinib and blinatumomab was safe and effective in patients with newly diagnosed PH+ ALL.
Kerri FitzgeraldAcute Myeloid Leukemia | December 19, 2022
The combination of decitabine/cedazuridine, venetoclax, and an IDH1 inhibitor was effective in treating IDH-mutated AML.
Kerri FitzgeraldMeeting News | December 19, 2022
Ivosidenib and azacitidine led to deep and durable remissions associated with clearance of IDH1-mutated newly diagnosed AML.
Kerri FitzgeraldHodgkin Lymphoma | December 10, 2022
The REALYSA study has garnered an enrollment rate of 54%—higher than typical clinical trial inclusion rates.
Kerri FitzgeraldMyeloproliferative Neoplasms | December 10, 2022
Selinexor plus ruxolitinib demonstrated promising clinical activity in patients with treatment-naïve myelofibrosis.
Kerri FitzgeraldMyeloma | December 10, 2022
A new study presented at the 2022 ASH Annual Meeting identified causes of the increased myeloma risk in Black Americans.